Summary
T-cell malignancies, including Peripheral T-cell Lymphomas (PTCL) and cutaneous entities such as Cutaneous T-cell Lymphoma (CTCL), comprise a diverse and often aggressive group of cancers that are generally associated with poorer clinical outcomes compared with B-cell malignancies.
The current CTCL treatment landscape includes approved therapies such as VALCHLOR, TARGRETIN, ADCETRIS, POTELIGEO, and LYMPHIR, among others.
For PTCL, the approved treatment landscape includes brentuximab vedotin (ADCETRIS; Takeda) for CD30-positive disease, romidepsin (ISTODAX; Bristol Myers Squibb), belinostat (BELEODAQ; Acrotech BioPharma), mogamulizumab (POTELIG...
